AR and prostate carcinoma: The VCaP cells used in our studies are slow-growing, androgen-sensitive, and possess a wild-type androgen receptor [40, 41], making them a bit closer to the nature of the indolent and [18F]FDG-PET “invisible” prostate carcinomas.